Boundless Bio, Inc. financial data

Symbol
BOLD on Nasdaq
Location
10955 Alexandria Way, Suite 100, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.53K % +1.25%
Debt-to-equity 43.4 %
Return On Equity -47.5 % +85.2%
Return On Assets -33.1 % +17.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 22.4M shares +0.38%
Common Stock, Shares, Outstanding 22.4M shares +0.59%
Entity Public Float 68.4M USD
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 22.4M shares +0.59%
Weighted Average Number of Shares Outstanding, Diluted 22.4M shares +0.59%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 48.3M USD -7.68%
General and Administrative Expense 19.5M USD +18.7%
Operating Income (Loss) -67.8M USD +1.39%
Nonoperating Income (Expense) 6.07M USD -21.5%
Net Income (Loss) Attributable to Parent -61.8M USD -1.15%
Earnings Per Share, Basic 7 USD/shares +16.2%
Earnings Per Share, Diluted 7 USD/shares +16.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 15M USD -62.7%
Cash, Cash Equivalents, and Short-term Investments 118M USD -29.6%
Assets, Current 120M USD -29.5%
Property, Plant and Equipment, Net 3.5M USD -11.6%
Operating Lease, Right-of-Use Asset 44.5M USD +40707%
Assets 169M USD -3.64%
Accounts Payable, Current 1.14M USD -55.3%
Employee-related Liabilities, Current 2.02M USD -29.1%
Liabilities, Current 11.8M USD +18.3%
Operating Lease, Liability, Noncurrent 46.7M USD
Liabilities 58.6M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax 50K USD -78.8%
Retained Earnings (Accumulated Deficit) -247M USD -33.4%
Stockholders' Equity Attributable to Parent 110M USD -33.3%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 110M USD -33.3%
Liabilities and Equity 169M USD -3.64%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.5M USD +7.9%
Net Cash Provided by (Used in) Financing Activities -924K USD -3081%
Net Cash Provided by (Used in) Investing Activities 3.06M USD -83.1%
Common Stock, Shares Authorized 700M shares 0%
Common Stock, Shares, Issued 22.4M shares +0.59%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.5M USD -898%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 15.5M USD -61.9%
Deferred Tax Assets, Valuation Allowance 58.8M USD +53.5%
Deferred Tax Assets, Gross 72.1M USD +84.9%
Depreciation 263K USD +11%
Payments to Acquire Property, Plant, and Equipment 59K USD -28.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -61.9M USD -2.04%
Property, Plant and Equipment, Gross 8.15M USD +9.02%
Operating Lease, Liability, Current 3.05M USD +2422%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure
Deferred Tax Assets, Operating Loss Carryforwards 27.6M USD +50.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 70M shares 0%
Unrecognized Tax Benefits 9.21M USD +14.5%
Operating Lease, Payments 100K USD -85.7%
Additional Paid in Capital 357M USD +2.01%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 317K USD +20.5%
Deferred Tax Assets, Net of Valuation Allowance 13.3M USD +1844%
Share-based Payment Arrangement, Expense 6.8M USD +5.95%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%